Does Medicare Cover Glp 1 for Weight Loss

Quick answer: As of now, Medicare does not cover GLP-1 drugs when prescribed only for weight loss under standard Part D plans. However, a new program called the Medicare GLP-1 Bridge begins July 1, 2026, which will provide access to certain GLP-1 weight loss drugs for eligible beneficiaries at a fixed $50 monthly copay.

Main Explanation

Medicare Part D prescription drug plans historically exclude weight loss medications. Drugs such as Wegovy, Ozempic, and others approved for weight loss are not covered under Part D when used solely for that purpose. However, some GLP-1 drugs may be covered if prescribed for other FDA-approved uses, such as type 2 diabetes, cardiovascular risk reduction, or obstructive sleep apnea.

Starting July 1, 2026, the Medicare GLP-1 Bridge program will temporarily cover three specific GLP-1 drugs for weight loss:

• Foundayo® (tablet)
• Wegovy® (injection or tablet)
• Zepbound® (KwikPen® only – single-dose pen and vials are not covered)

Under this program, eligible beneficiaries will pay a flat $50 per month, regardless of income. This copay does not count toward your Part D deductible or out-of-pocket limit. The Bridge program runs through December 31, 2027, after which it will be replaced by the BALANCE Model.

Are You Eligible? (Decision Framework)

The Medicare GLP-1 Bridge program has four requirements. You must meet all of the following to qualify:

1. You have Medicare Part D drug coverage – either through a standalone drug plan or a Medicare health plan that includes drug coverage. Certain special plan types (e.g., private fee-for-service, cost contracts, PACE) may not qualify.
2. You are not already receiving a GLP-1 drug through your Medicare drug plan for other conditions like diabetes or sleep apnea. If you currently get a GLP-1 through Part D for another medical reason, you must continue through your plan and are not eligible for the Bridge.
3. You do not have type 2 diabetes, moderate-to-severe sleep apnea, or cardiovascular disease that would otherwise qualify you for Part D coverage of GLP-1 drugs.
4. You meet any additional eligibility criteria as determined by the program (enrollment steps may be required).

If you meet all four, you can access the covered GLP-1 drugs at the $50 copay starting July 1, 2026.

Practical Takeaways

• If you need GLP-1 drugs for weight loss now, Medicare Part D does not cover them for that purpose. You may need to explore other options or wait for the GLP-1 Bridge program.
• If you have a medical condition (like type 2 diabetes, cardiovascular disease, or sleep apnea) that GLP-1 drugs can treat, your Medicare Part D plan may already cover them – check your plan’s formulary.
• Mark your calendar for July 1, 2026 – that’s when the Bridge program starts. Eligible individuals can get Wegovy, Foundayo, or Zepbound (KwikPen) for $50/month.
• Call 1-800-MEDICARE (1-800-633-4227) if you’re unsure about your plan type or eligibility.

References Medicare.gov – Weight loss drugs: https://www.medicare.gov/coverage/weight-loss-drugs Medicare.gov – GLP-1 Drugs for $50 a Month: https://www.medicare.gov/publications/12234-medicare-glp-1-bridge-glp-1-drugs-for-50-a-month.pdf CMS.gov – Medicare GLP-1 Bridge: https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge Humana – Does Medicare cover weight loss drugs? https://www.humana.com/medicare/medicare-resources/does-medicare-cover-weight-loss-drugs Aetna – Medicare GLP-1 Bridge Coverage: https://www.aetna.com/medicare/understanding-medicare/medicare-glp-1-weight-loss-drug-coverage.html American College of Gastroenterology – Anti-Obesity Drugs Will Not be Covered: https://gi.org/journals-publications/acg-blog/anti-obesity-drugs-will-not-be-covered-by-medicare-and-medicaid-in-2026 Wegovy.com – Medicare Part D Information: https://www.wegovy.com/medicare.html Wellcare – Does Medicare Cover Weight-Loss Drugs? https://www.wellcare.com/en/resources/does-medicare-cover-weight-loss-drugs Congress.gov – Medicare Coverage of GLP-1 Drugs: https://www.congress.gov/crs-product/IF12758